- Labcorp anticipates an adjusted EPS (Earnings Per Share) of $14.30 to $15.40 for the year 2024.
- The company’s fourth quarter results showcased an adjusted EPS of $3.30.
- The revenue for the fourth quarter stood at $3.03 billion.
- The adjusted operating margin for the same period was at 13%.
- Labcorp’s trailing 12-month net book-to-bill ratio was recorded at 1.04%.
- There have been 10 purchases and 10 holds of Labcorp’s shares, with no recorded sales as of yet.
A look at Laboratory Corporation of America Holdings Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Laboratory Corporation of America Holdings, a clinical laboratory company, has received a strong overall outlook from Smartkarma Smart Scores. The company scored a 3 out of 5 in value, indicating that it is currently priced at a fair value. In terms of dividend, the company scored a 2 out of 5, suggesting that it may not be the best option for investors seeking regular dividend payouts. However, Laboratory Corporation of America Holdings scored a 3 out of 5 in growth, indicating potential for future growth in the company’s operations.
Additionally, the company received a score of 2 out of 5 in resilience, which suggests that it may be more susceptible to economic downturns. However, Laboratory Corporation of America Holdings received a high score of 4 out of 5 in momentum, indicating that the company has been performing well in the market recently. Overall, the Smartkarma Smart Scores suggest a positive long-term outlook for Laboratory Corporation of America Holdings, with potential for growth and strong market performance in the future.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
